Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug hopes to boost brain recovery after stroke

NCT ID NCT04309474

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tested an experimental drug called elezanumab in 121 people who had an acute ischemic stroke. The goal was to see if it could safely improve neurological function and reduce disability compared to a placebo. Participants received the drug or placebo by IV within 24 hours of the stroke and then every 4 weeks for nearly a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
elezanumab (also called ABT-555)
What this could lead to
If it works, this could point toward a new treatment to help people recover better after a stroke and reduce long-term disability.
What could go wrong
This is a small, early Phase 2 proof-of-concept study, so results may not confirm benefit. The drug is still experimental, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

121 people

The number who actually took part.

Started

Nov 2020

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of acute ischemic stroke, supported by acute brain computed tomography (CT) or magnetic resonance imaging (MRI) consistent with the clinical diagnosis. * Able to randomize within 24 hours of last known normal. * National Institute of Health Stroke Scale (NIHSS) total score of 7 to 21, inclusive. * Participants or their legally authorized representative confirms that prior to index stroke, no significant impairment in participant's ability to perform activities of daily living without assistance. Exclusion Criteria: * Evidence of severe stroke on imaging based on available acute imaging studies performed under the standard of care. * Evidence of acute seizure at the onset of index stroke without conclusive imaging of ischemic stroke. * Evidence of acute myocardial infarction. * Symptoms are considered likely to resolve within the subsequent few hours (e.g., transient ischemic attack \[TIA\]). * Known history prior to randomization of clinically significant medical conditions (other than current acute ischemic stroke) or any other reason, including any physical, psychological, or psychiatric condition that in the investigator's opinion would compromise the safety or interfere with the participant's participation in this study. * Known medical history of repeated episodes of complex migraine. Participants with history of complex migraine, but with imaging conclusively demonstrating an acute ischemic stroke are still allowed. * Female who is pregnant, breastfeeding, or considering becoming pregnant during the study or for within 39 weeks (5 half-lives) after the last dose of study drug. * Known receipt of any investigational product within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug. No current enrollment in another interventional clinical study, including pharmacologic and behavioral interventional studies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke

Contacts and locations

Locations

  • Baylor Scott & White Medical Center- Temple /ID# 225513

    Temple, Texas, 76508-0001, United States

  • Cleveland Clinic Main Campus /ID# 214635

    Cleveland, Ohio, 44195, United States

  • Columbia University Medical Center /ID# 215122

    New York, New York, 10032-3729, United States

  • Complejo Hospitalario Universitario A Coruña /ID# 230080

    A Coruña, A Coruna, 15006, Spain

  • Duplicate_CHA University Bundang Medical Center /ID# 233503

    Seongnam-si, Gyeonggido, 13496, South Korea

  • Duplicate_Mayo Clinic /ID# 217567

    Jacksonville, Florida, 32224, United States

  • Duplicate_Pusan National University Hospital /ID# 233769

    Busan, Busan Gwang Yeogsi, 49241, South Korea

  • Duplicate_Royal North Shore Hospital /ID# 239083

    St Leonards, New South Wales, 2065, Australia

  • Duplicate_University of Kentucky Chandler Medical Center /ID# 216394

    Lexington, Kentucky, 40536, United States

  • Fukuoka University Chikushi Hospital /ID# 240629

    Chikushino-shi, Fukuoka, 818-8502, Japan

  • Fukuoka Wajiro Hospital /ID# 239810

    Fukuoka, Fukuoka, 811-0213, Japan

  • Georgetown University Hospital /ID# 216481

    Washington D.C., District of Columbia, 20007, United States

  • Hackensack Univ Med Ctr /ID# 218200

    Hackensack, New Jersey, 07601, United States

  • Hamilton General Hospital /ID# 218970

    Hamilton, Ontario, L8L 2X2, Canada

  • Hospital Donostia /ID# 218034

    Donostia / San Sebastian, Guipuzcoa, 20014, Spain

  • Hospital Universitario La Paz /ID# 216380

    Madrid, 28046, Spain

  • Hospital Universitario Vall de Hebron /ID# 217087

    Barcelona, 08035, Spain

  • Hospital Universitario Virgen Macarena /ID# 216382

    Seville, 41009, Spain

  • Hospital Universitario Virgen del Rocio /ID# 216339

    Seville, 41013, Spain

  • Lehigh Valley Health Network /ID# 242446

    Allentown, Pennsylvania, 18103, United States

  • Long Beach Medical Center /ID# 217210

    Long Beach, California, 90808-1731, United States

  • Mayo Clinic Arizona /ID# 214957

    Phoenix, Arizona, 85054, United States

  • Nagano Municipal Hospital /ID# 240622

    Nagano, Nagano, 3818551, Japan

  • National Hospital Organization Kagoshima Medical Center /ID# 240021

    Kagoshima, Kagoshima-ken, 892-0853, Japan

  • Northwestern University Feinberg School of Medicine /ID# 215047

    Chicago, Illinois, 60611-2927, United States

  • OSI Ezkerraldea-Enkarterri-Cruces /ID# 217529

    Barakaldo, Vizcaya, 48903, Spain

  • Samsung Medical Center /ID# 234241

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Hospital /ID# 233473

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • St. Luke's Marion Bloch Neuroscience Institute /ID# 215028

    Kansas City, Missouri, 64111-3220, United States

  • The Ohio State University /ID# 215036

    Columbus, Ohio, 43210, United States

  • The Royal Melbourne Hospital /ID# 240178

    Parkville, Victoria, 3050, Australia

  • Thomas Jefferson University Hospital /ID# 215469

    Philadelphia, Pennsylvania, 19107, United States

  • Tufts Medical Center /ID# 215053

    Boston, Massachusetts, 02111-1552, United States

  • UH Cleveland Medical Center /ID# 215372

    Cleveland, Ohio, 44106, United States

  • University of Alberta Hospital /ID# 218370

    Edmonton, Alberta, T6G 2B7, Canada

  • University of Louisville Hospital /ID# 217569

    Louisville, Kentucky, 40202, United States

  • University of Mississippi Medical Center /ID# 217587

    Jackson, Mississippi, 39216-4500, United States

  • University of New Mexico School of Medicine /ID# 216827

    Albuquerque, New Mexico, 87131-0001, United States

  • University of Texas Health Science Center at Houston /ID# 215018

    Houston, Texas, 77030-1501, United States

  • University of Virginia /ID# 215757

    Charlottesville, Virginia, 22908, United States

  • Washington University-School of Medicine /ID# 214526

    St Louis, Missouri, 63110, United States

  • Yamaguchi Grand Medical Center /ID# 239892

    Hohu-shi, Yamaguchi, 747-8511, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.